Precision Biosciences has patented a mitochondria-targeting engineered meganuclease (MTEM) that can modify human mitochondrial DNA. The technology involves genetically modifying eukaryotic cells by editing the mtDNA, potentially opening new avenues for gene therapy and biotechnology. GlobalData’s report on Precision Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Precision Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Precision Biosciences, Gene splicing using nucleases was a key innovation area identified from patents. Precision Biosciences's grant share as of February 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.

Engineered meganucleases for modifying human mitochondrial dna

Source: United States Patent and Trademark Office (USPTO). Credit: Precision Biosciences Inc

A recently granted patent (Publication Number: US11866747B2) discloses a novel mitochondria-targeting engineered meganuclease (MTEM) designed to bind and cleave specific recognition sequences within mitochondrial genomes of eukaryotic cells. The MTEM consists of an engineered meganuclease fused with a mitochondrial transit peptide (MTP), with additional components such as a nuclear export sequence (NES) for enhanced functionality. The amino acid sequences of the components are specified in the claims, providing a detailed blueprint for the construction of the MTEM.

Furthermore, the patent also covers the use of polynucleotides encoding the MTEM and their incorporation into recombinant adeno-associated viruses (AAVs) for targeted delivery into cells. The AAVs are designed to carry the MTEM gene along with specific promoters and capsids for efficient gene expression and delivery. The claims outline various configurations of the MTEM, MTP, NES, and promoters, emphasizing the versatility and customization options available for researchers looking to utilize this technology for mitochondrial genome editing. Overall, the patent provides a comprehensive framework for the development and application of the MTEM technology in genetic engineering and therapeutic interventions.

To know more about GlobalData’s detailed insights on Precision Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies